RJF Share Price Performance
€2.71
-0.56 (-17.13%)
17.6% undervalued intrinsic discount
€3.29
Fair Value
Price €2.71
Janpeo €3.29
Fair Value€3.29
Share Pricen/a
Narrative Update • May 07
Laboratorio Reig Jofre, S.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
RJF Community Narratives
JA
Fair Value
·Fair Value €3.29 17.6% undervalued intrinsic discount
Laboratorio Reig Jofre will experience a revenue boost of 8.51%
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Trending Discussion
Recently Updated Narratives
JA
Reig Jofre Will Emerge Stronger Despite Temporary Setbacks
Fair Value: €3.29 17.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Laboratorio Reig Jofre, S.A. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 31, 2026
- 0.054
- 58.80%
- 1.32%
- 36.7%
About RJF
- Founded
- 1929
- Employees
- 1400
- CEO
- WebsiteView website
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.
